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Purpose: To evaluate if physiotherapy can contribute to the quality of 
service provided to Women with Breast Cancer who underwent sentinel 
lymph node biopsy (SLNB).Methods: This Quasi-experimental study 
addressed a sample of 172 women with breast cancer who underwent 
surgery with SLNB, 90 were included in the control group and 82 in the 
experimental group. We used the EORTC C30 and BR23 questionnaires 
to collect data about the quality of life (QoL) in the course of the first 9 
months after surgery (months 1, 3, 6 and 9). The experimental group 
was submitted to specific physiotherapy techniques (individual and 
group treatments) in functional rehabilitation of women with breast 
cancer while the control group was the target of assessments only. 
Poisson regression was used to perform the calculation of the Relative 
Benefit (aRB) and Relative Risk (aRR) adjusted for several confounding 
factors at the baseline of the study. The significance level used in the 
study was 5% and the confidence interval (CI) was established at 95%. 
All calculations were performed using the SPSS software, 20th 
version.Results: In the third month after surgery the experimental group 
showed a higher proportion of patients with substantial clinical 
improvement in the Global Health Status (GHS) (aRB=2.230; p=0.014) 
and a lower risk of degradation of the GHS,	   (aRR=0.384; p=0.011), 
Physical Function (PF) (aRR=0.484; p=0.035), and Arm Symptoms 
(BRAS) (aRR=0.159; p=0.007), when compared to the control group. 
Between the 1st and 6th month after surgery, physiotherapy seems to 
act as a protective factor on the degradation of GHS and PF. 
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Introduction 
 
The modalities of breast cancer surgery which, in addition to breast surgery, 
recur to Sentinel Lymph Node Biopsy (SLNB) have significantly reduced 
morbidity of the upper limb and trunk on the surgery side when compared to 
surgeries in which an Axillary Lymph Node Dissection is performed [1-6]. 
However, in the acute survival phase [7,8], when oncological therapies are 
performed during the first year following diagnosis, the effect of therapies such as 
chemotherapy, radiotherapy, hormone therapy, and immunotherapy can 
overcome the lower aggressiveness of the surgery, leading to no differences in  
quality of life  (QoL) between the two groups of patients [9-12].  
There is evidence that it is possible to prevent some complications (or 
minimize their effect) throughout the acute phase of cancer treatment with 
oncological therapies through an early rehabilitation program [13-19] and it is 
known that physiotherapy and a program with specific exercises can contribute to 
the improvement in QoL in women with breast cancer throughout the acute 
phase of survival [20-32]. However, clinical practice suggests that patients 
undergoing SLNB surgery are rarely included in a functional rehabilitation 
program because it is assumed that in this surgery there is an absence of 
morbidity and consequently a minimal impact in their QoL. It is therefore 
important to clarify whether physiotherapy can contribute to the improvement in 
QoL in women with breast cancer undergoing SLNB surgery, to demonstrate 
whether physiotherapy can contribute to the quality of care provided to this 
group of patients. The purpose of this study was to evaluate whether 
physiotherapy can contribute to the improvement of the various dimensions of 
QoL in women with breast cancer undergoing SLNB surgery and other cancer 
therapies during the first 9 months after surgery. It also sought to verify whether 
physiotherapy can act as protective factor in the prevention of global QoL 
degradation, function, and symptoms in this group of patients. 
 
 
Between the 1st and 9th month after surgery the experimental group 
showed a higher proportion of patients with notable clinical improvement 
in the GHS (aRB=1.905; p=0.038) and in the BRAS (aRB=1.761; 
p=0.029) and a lower risk of degradation of the GHS (aRR=0.287; 
p=0.010) and BRAS (aRR=0.265; p=0.0421) scales, when compared to 
the control group. Conclusions: In the course of the acute survival phase, 
physiotherapy can help to improve the QoL of women with breast cancer 
who underwent surgeries with SLNB, giving a positive contribution to the 
quality of service provided to this group of patients. 
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Material and Methods 
 
A Quasi-Experimental study was carried out. QoL in women with breast 
cancer was evaluated through a questionnaire developed by the European 
Organization for Research and Treatment of Cancer (EORTC): QLQ-C30 
(general for cancer patients) and its complementary questionnaire QLQ-BR23 
(specific for breast cancer). The psychometric properties of this questionnaire 
have been tested in several studies and it has been concluded that this can be 
considered a valid instrument [32-34], being validated for the Portuguese 
population [35-37]. According to the EORTC guidelines, the global scales of QoL 
in terms of function and symptoms are transformed into values on a scale from 0 
to 100. A high score represents a high response level. Thus, a high score for a 
functional scale represents a high and healthy level of functioning; a high score 
for the overall health status of QoL represents a high QoL, but a high score for a 
symptom scale represents a high level of symptomatology or problems [38]. 
Sociodemographic and clinical data were also collected and a questionnaire was 
constructed for this purpose. 
 A request for permission to use the questionnaires (EORTC QLQ - 30 and 
QLQ - BR23) was submitted to EORTC and the authorization was granted in 
September 2012. The project was submitted to an evaluation by the Research 
Council and the Ethics Council of the Francisco Gentil Portuguese Institute of 
Oncology in Lisbon (Instituto Português de Oncologia de Lisboa, Francisco 
Gentil - IPOLFG). The Clinical Research Unit of the IPOLFG gave a favorable 
opinion to the study on 13 March 2013, and assigned the study with the code 
UIC / 816. 
 The independent exposure variable of primary importance for this study was 
the physiotherapy technique (individual or group treatment) applied in the 
functional rehabilitation of women with breast cancer [39, 40]. Age, marital 
status, occupation, level of education, histopathology, type of surgery, and 
oncological therapies were the variables used to characterize the baseline study 
sample. The dependent variables analyzed were Global Health Status (GHS), 
Physical Functioning (PF), Role Functioning (RF), Emotional Functioning (EF), 
Social Functioning (SF), Future Perspective (BRFU), and Body Image (BRBI) 
for functioning scores; and Fatigue (FA), Pain (PA), Breast Symptoms, and Arm 
Symptoms (BRAS) for symptoms scores. From the concept “Minimal Clinically 
Important Difference” [38, 41-44]    the following variables were defined: 
Improvement with Clinical Relevance (when there was a difference between the 
scores of two evaluations greater than 5 positive points in the global and 
functional QoL scales and 5 negative points in the symptoms scales); 
Conservative Clinical Improvement (when there was a difference between the 
scores of two evaluations greater than 10 positive points in the global and 
functional QoL scales and 10 negative points in the symptoms scales), and 
Clinical Degradation (when the difference between the scores of two evaluations 
was greater than 5 negative points in the global and functional QoL scales or 
greater than 5 positive points in the symptoms scales). The definition of these 
variables allowed the calculation of the Relative Benefit (RB) and Relative Risk 
(RR) in the dependent variables of the study. 
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 The following exclusion criteria were defined:  non-acceptance of the patients 
to the intervention and study; other pathologies that could interfere with the 
results of the study (history of previous oncological pathology, relapses, joint 
pathologies, cognition alterations). 
 In this study, the GHS scale was chosen to calculate the sample size, since it 
is the one most often used in the reference literature [9-12]. As the study had four 
evaluation moments, we opted to choose the moment when the group of patients, 
according to our literature survey, would have a lower score in the parameter in 
question (GHS), that is, at 6 months after surgery. We decided to use a combined 
average and a combined standard deviation of the studies consulted, taking into 
account the sample size of the studies in the combined calculation. A 0.05 
statistical significance level and a 0.80 power were considered. Regarding the 
expected effect, we used the values obtained in an exploratory study [45], in 
which the clinical improvement for the GHS variable was moderate, that is, 
improvement of the median value of this parameter was obtained between 10 and 
20 following the physiotherapy. In this study we used the minimum value 
corresponding to a moderate clinical improvement, which is 10 [43]. In order to 
evaluate the effectiveness of the program, we deemed it appropriate to make a 
longitudinal observation of the outcomes at 3, 6 and 9 months after surgery. 
According to the calculation of the sample size, the sample should have 
approximately 60 patients in each group, making a total number of 120 patients. 
The study sample comprised 172 women with breast cancer undergoing sentinel 
lymph node biopsy and other cancer therapies followed in the IPOLFG from 
March 2013 to November 2014. Of the 172 patients, 90 were included in the 
Control Group and 82 in the Experimental Group. All participants had access to 
an explanatory term of study to give informed consent. They were also informed 
about the protection of personal data. After their consent to participate in the 
study, inclusion in the Experimental or Control Group was at the choice of each 
patient. Data were collected at the same institution at four moments: 1st moment 
of evaluation (3 to 4 weeks post-surgery); 2nd moment of evaluation (3 months 
post-surgery); 3rd moment of evaluation (6 months post-surgery); 4th moment of 
evaluation (9 months post-surgery). 
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Figure 1. Evolution of the sample throughout the study 
 
 
Patients who gave their consent and joined the Experimental Group 
underwent physiotherapy treatments (individual and group treatments) 
simultaneously with the oncology therapy protocol defined in the Therapeutic 
Decision Consultation (TDC), during the first 9 months after surgery. Individual 
physiotherapy treatments were performed by the same physiotherapist (25 years 
of experience in oncology) and group treatments (movement class) by two 
physiotherapists (25 and 36 years of experience in oncology). Individual 
physiotherapy treatments started 3 to 4 weeks after surgery, according to the 
protocol followed by the institution. After each moment of evaluation, whenever 
there was a loss of function or aggravation of the symptomatology, the patients 
had again the support of the physiotherapist. The type of support given by the 
physiotherapist always depended on the complications presented by the patient 
and the protocol of oncological therapies defined in the TDC. Individual 
physiotherapy treatments, in most cases, took place over three weeks, with an 
n=221 
Patients referenced by the 
Multidisciplinary Breast 
Nursing Unit Consultation in the IPOLFG. 
Screening Interview 	  
49 excluded patients: 
4 – joint pathology 
2 – previous oncological pathology 
1 – undergoing hemodialises 
4 – surgical intervention more than 6 weeks ago 
1 – illiterate 
1 – cognitive problems 
36 – did not agree to be integrated in the study 
 
 
Inclusion / exclusion 
criteria 
n=172 
Initial sample 
n=82   
Experimental Group  
Baseline of the study 
 
   B   
 
 
 
 	  	  	  	  	  	  	  	  	  	  
Nn=90  
Control Group 
Baseline of the study 
 
 
 
 
 
 n=77 
2nd moment of evaluation 
n=78 
2nd moment of evaluation 
n=76 
3rd moment of evaluation 
n=75 
3rd moment of evaluation 
n=75 
4th moment of evaluation 
n=75 
4th moment of evaluataion 
5 dropouts 
1 dropout 
1 death 
12 dropouts 
3 dropouts 
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average of 12 treatments per patient. Techniques were used to increase articular 
amplitudes through maneuvers that promote pain relief and scar mobilization, 
and that work in breast and chest wall edemas, web syndrome, and sensitivity 
alterations (mobilization of the shoulder girdle, mobilization of the scar, manual 
lymphatic drainage, muscle stretching and neurodynamic exercises). After 
reaching normal joint amplitude or an amplitude near the maximum at the level 
of the joints of the upper limb and trunk in the affected side, the patients joined 
a movement class (group exercises), aiming to increase or maintain joint 
amplitudes of the shoulder girdle and cervical spine, increase muscle strength, 
and increase endurance. Patients undergoing radiotherapy treatments (RT) 
remained in the class until one to two weeks after the end of therapy and were 
informed about the need to do some of the class exercises in the following weeks. 
The classes took place five times per week, for a period of 20 to 30 minutes per 
day, and lasted for an average of 10 weeks. The exercise regimen consisted of 
cervical mobilization exercises, mobilization of the shoulder girdle, trunk 
mobilization, muscle stretching, neurodynamic exercises, postural exercises, and 
relaxation exercises. In the Control Group, the patients who gave their consent 
and were included in this study did not undergo physiotherapy treatments and 
only received evaluations during the first 9 months of the protocol for cancer 
therapies defined in the TDC. The same evaluation protocol was applied to the 
Experimental Group. 
We used bivariable descriptive statistics for baseline sample characterization. 
Poisson regression was used to perform the calculation of the Relative Benefit 
(aRB) and Relative Risk (aRR) adjusted for several confounding factors at the 
baseline of the study [46]. The significance level used in the study was 5% and 
the confidence interval (CI) was established at 95%. All calculations were 
performed using the SPSS software, 20th version. 
 
 
Results 
 
We found that the continuous variables at the baseline of the study (3 to 4 
weeks after surgery) did not follow a normal distribution, so the median was used 
as the first comparative measure. 
 At the baseline of the study (n = 172) we can assume statistical homogeneity 
of the two groups in terms of “Time after surgery”. The groups did not present a 
statistical homogeneity in the variables “Age”, “Number of School Years” and 
“Occupation” (Table 1). The Experimental Group consisted of younger women, 
with higher level of literacy and non-retired when compared to the Control 
Group. Regarding the clinical characterization, there was a statistical 
homogeneity in the two groups in the variables “Histopathology”, “Oncology 
Therapies before surgery”, “QT in the treatment protocol” and “RT + Hormone 
Therapy after surgery”. 
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Table 1: Comparative analysis of the Experimental versus Control Group at the baseline of the study (approximately 
1 month after surgery) 
Variable in 
analysis (Baseline 
of the study) 
Categories of the 
variable 
Statistical 
Measures 
Experimental 
Group 
n= 82 
Control 
Group 
n= 90 
p-Value 
Age  Median 
Min-Máx 
54.50 
31 – 78 
61.15 
38 – 81 
< 0.001 
Number of school 
years 
 Median 
Min-Máx 
9.50 
3 – 20 
8.58 
2 – 20 
0.017 
Time after surgery 
(days) 
 Median 
Min-Máx 
23 
22 – 26 
23 
22 - 26 
0.941 
Marital Status 
 
 
 
 
Not married 
Married 
Divorced 
Widow 
n(%) 
n(%) 
n(%) 
n(%) 
8 (9.8%) 
56 (68.3 %) 
14 (17.1%) 
4 (4.9%) 
8 (8.9%) 
65 (72.2%) 
8 (8.9%) 
9 (10.0%) 
 
0.276 
Occupation Retired 
Non-retired 
n(%) 
n(%) 
20 (24.4 %) 
62 (75.6%) 
49 (54.4%) 
41 (45.6%) 
 
< 0.001 
 
Histopathology 
Carcinoma InSitu 
 
Invasive Carcinoma 
n(%) 
 
n(%) 
13 (15.9%) 
 
69 (84.1%) 
9 (10.0%) 
 
81 (90%) 
 
0.264 
Conservative 
VS. 
Mastectomy 
Conservative 
 
Mastectomy 
n(%) 
 
n(%) 
52 (63.4%) 
 
30 (36.6%) 
76 (84.4%) 
 
14 (15.6%) 
 
0.002 
Oncology Therapies 
before surgery 
Yes 
No 
n(%) 
n(%) 
 
0 (0%) 
82 (100%) 
0 (0%) 
90 (100%) 
 
Chemotherapy in the 
treatment protocol 
No 
Yes 
 
n(%) 
n(%) 
54 (65.9%) 
28 (34.1%) 
61 (67.8%) 
29 (32.2%) 
 
0.789 
RT + HT exclusive 
post-surgery 
No 
Yes 
n(%) 
n(%) 
46 (56.1%) 
36 (43.9%) 
42 (46.7%) 
48 (53.3%) 
 
0.226 
Global Health Status  Median 
Min-Max 
50.00 
16.67-83.33 
66.66 
8.33-100 
< 0.001 
Physical Functioning  Median 
Min-Max 
80.00 
13.33-100 
86.66 
26.67-100 
< 0.001 
 
Role  
Functioning 
 Median 
Min- Max 
66.66 
0.00-100 
66.66 
0.00-100 
0.039 
Emotional 
Functioning 
 Median 
Min-Max 
66.66 
0.00-100 
75,00 
8.33-100 
0.014 
Social  
Functioning 
 Median 
Min-Max 
66.66 
0.00-100 
83,33 
0.00-100 
0.002 
 
Future Perspective  Median 
Min-Max 
33.33 
0.00-100 
66,66 
0.00-100 
0.003 
Body Image  Median 
Min-Max 
83.33 
0.00-100 
100 
25.00-100 
0.001 
 
Fatigue  Median 
Min-Max 
33.33 
0.00-100 
22,22 
0.00-88.89 
0.004 
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Pain  Median 
Min-Max 
33.33 
0.00-83.33 
16,66 
0.00-100 
0.008 
Breast Symptoms  Median 
Min-Max 
33.33 
0.00-100 
25.00 
0.00-91.67 
0.059 
Arm Symptoms  Median 
Min-Max 
33.33 
0.00-100 
11.11 
0.00-66.67 
< 0.001 
p-value obtained by the Mann-Whitney Test - Comparison of the numerical variables “age” and “number of school years” and the ordinal variable 
“literacy level”. Comparison of dependent (continuous) variables, at the 1st moment of evaluation, between study groups. 
p-value obtained by the Chi-square Test - Comparison of the variables “Marital status”, “Occupation”, “Histopathology”, “Conservative VS. 
Mastectomy”, “Chemotherapy in the treatment protocol”, “RT + HT exclusive post-surgery”. 
QT - Chemotherapy; RT - Radiotherapy; HT - Hormone therapy; IT – Immunotherapy 
All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high / healthy level of 
functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high 
level of symptomatology / problems [38]. 
 
The groups did not present statistical homogeneity, in the variable 
“Conservative Surgery vs. Mastectomy” (Table 1). The Experimental Group 
presented a higher proportion of women with mastectomies. In the evaluation of 
the Global QoL scales, function and symptom at the baseline of the study (n = 
172), there was no statistical homogeneity in the two compared groups in most of 
the variables under analysis. The only exception was the variable “Breast 
Symptoms”. At the Baseline, the Experimental Group presented higher severity 
when compared to the Control Group. (Table 1). 
 
 
Most Important Results in the Analysis Performed 
Between the 1st and 3rd Month after Surgery (n = 155) 
  
In this analysis only the measurements of Relative Benefit (RB) and Relative 
Risk (RR) with a substantial effect in the study are presented. As mentioned 
above, the groups at the baseline of the study were not homogeneous regarding 
some sociodemographic, clinical, and QoL variables. A model to adjust for the 
confounding baseline variables (Poison regression) was therefore applied. The 
following variables were included: age, number of school years, occupation, type 
of surgery, and baseline QoL variables. After adjustment for non-homogeneous 
factors at the baseline of the study (Table 2), the Relative Benefit value (aRB) 
shows that the Experimental Group (between the 1st and 3rd month post-
surgery) had a higher proportion of patients with a clinical improvement in the 
GHS variable (aRB = 2.230, p = 0.014), corresponding to a clinical improvement 
123% higher than that observed in the Control Group. 
Concerning the variable “Clinical Degradation”, after adjustment for 
confounding factors at the baseline of the study, we found that in GHS variables 
(aRR = 0.384, p = 0.011), PF (aRR = 0.484, p = 0.035), and BRAS (aRR = P 
= 0.007), the physiotherapy may have acted as a protective factor between the 
1st and 3rd month post-surgery (1st and 2nd moments of evaluation), and there 
was less degradation in these scales in the function and symptoms in the 
Experimental Group when compared to the Control Group. We can say that in 
the Experimental Group, between the 1st and 3rd month after surgery, there was 
a reduction in the risk of clinical degradation in the scales: GHS - relative risk 
reduction of 61.6%; PF - relative risk reduction of 51.6%; BRAS - relative risk 
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reduction of 84.1%. In the BRFU variable, the p-value reveals a trend (p <0.10), 
and the aRR values may suggest that the individuals in the Experimental Group 
had a lower degradation in this function scale (Table 2). 
 
Table 2: Most important results (n = 155) in the analysis performed between the 1st and 3rd month post-surgery 
(1st and 2nd moments of evaluation) 
Variable in analysis  RB aRB RR aRR 
Clinical Improvement “Global Health 
Status” 
2.76 
P<0.001  ͣ
2.230 
P=0.014 ᵇ 
- - 
 Clinical Improvement “Physical 
Functioning” 
1.75 
P=0.001 ͣ 
1.320 
P=0.314 ᵇ 
- - 
Clinical Improvement “Arm 
Symptoms” 
1.72 
P<0.001 ͣ 
1.341 
P=0.212 ᵇ 
- - 
Conservative Clinical Improvement 
“Global Health Status” 
2.026 
P=0.038 ͣ  
1.501 
P=0.30 ᵇ 
- - 
Conservative Clinical Improvement 
“Physical Functioning” 
2.448 
P=0.001 ͣ 
1.530 
P=0.272 ᵇ 
- - 
Conservative Clinical Improvement 
“Social Functioning” 
1.59 
P=0.037 ͣ 
1.29 
P=0.395 ᵇ 
- - 
Conservative Clinical Improvement 
“Pain” 
1.58 
P=0.018 ͣ 
1.330 
P=0.212 ᵇ 
- - 
Conservative Clinical Improvement 
“Arm Symptoms” 
1.728 
P<0.001 ͣ 
1.341 
P=0.212 ᵇ 
 
- 
 
- 
Clinical Degradation “Global Health 
Status” 
- - 0.265 
P<0.001  ͣ
0.384 
P=0.011ᵇ 
Clinical Degradation 
“Physical Functioning” 
- - 0.337 
P<0.001  ͣ
0.484 
P=0.035 ᵇ 
Clinical Degradation 
“Future Perspective” 
- - 0.295 
P<0.001  ͣ
0.446 
P=0.085 ᵇ 
Clinical Degradation 
“Breast Symptoms” 
- - 0.555 
P=0.017 ͣ 
0.713 
P=0.290 ᵇ 
Clinical Degradation 
“Arm Symptoms” 
- - 0.168 
P<0.001  ͣ
0.159 
P=0.007 ᵇ 
RB - Relative Benefit; aRB - Adjusted Relative Benefit; RR - Relative Risk; aRR - Adjusted Relative Risk 
ͣ p-value obtained by the Chi-square Test - Comparison between groups, of the percentage of individuals who obtained a Clinical Improvement, 
Clinical Conservative Improvement, and Clinical Degradation  in the different global QoL scales, function, and symptom, between the 1st and 2nd 
moment of evaluation. 
ᵇ p-Value obtained by the Wald Test - Comparison between groups, of the percentage of individuals who obtained a Clinical Relevant Improvement, 
Improvement with Conservative Clinical Relevance, and Clinical Degradation in the different global QoL, function, and symptom scales, between the 
1st and 2nd moments of evaluation, making an adjustment for the confounding variables at the baseline of the study. 
In bold - Only the RB, aRB, RR, and aRR values that, still showed a statistically significant difference (or a trend) between groups, after being 
adjusted for non-homogeneous factors at the baseline of the study. 
 
 
Most Important Results in the Analysis Performed 
Between the 1st and 6th Month after Surgery (n = 151) 
  
In the analysis performed between the 1st and 6th month after surgery (1st 
and 3rd moments of evaluation), in the calculation of the RB of the variable 
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“Clinical Improvement” and “Conservative Clinical Improvement”, after 
adjustment for non-homogeneous factors at the baseline of the study, we verified 
that there are no statistically significant differences between groups, allowing us 
to say that the RB is no longer statistically significant after adjustment for non-
homogeneous factors (Table 3). 
 
Table 3: Most important results (n = 151) in the analysis performed between the 1st and 6th month after surgery 
(1st and 3rd moments of evaluation). 
Variable in Analysis RB aRB RR aRR 
Clinical Improvement “Global 
Health Status” 
1.802 
P=0.002 ͣ 
1.474 
P=0.174 ᵇ 
  
Clinical Improvement “Physical 
Functioning” 
1.776 
p=0.001 ͣ 
1.135 
p=0.656 ᵇ 
  
Clinical Improvement 
“Future Perspetive” 
1.678 
p=0.020  ͣ 
1.573 
p=0.144 ᵇ 
  
Clinical Improvement 
“Fatigue” 
1.714 
p=0.019 ͣ 
1.152 
p=0.649 ᵇ 
  
Clinical Improvement 
“Pain” 
1,725 
p=0.003 ͣ 
1.429 
p=0.202 ᵇ 
  
Clinical Improvement “Arm 
Symptoms” 
1.974 
p<0.001 ͣ 
1.440 
p=0.163 ᵇ 
  
Conservative Clinical Improvement 
“Global Health Status” 
1.625 
p=0.056 ͣ 
1.051 
p=0.885 ᵇ 
  
Conservative Clinical Improvement 
“Physical Functioning” 
2.33 
p=0.005 ͣ 
1.074 
p=0.866 ᵇ 
  
Conservative Clinical Improvement 
“Future Perspetive” 
1.678 
p=0.020 ͣ 
1.573 
p=0.144 ᵇ 
  
Conservative Clinical Improvement 
“Pain” 
1.802 
p=0.002 ͣ 
1.472 
p=0.173 ᵇ 
  
Conservative Clinical Improvement 
“Arm Symptoms” 
1.901 
p<0.001 ͣ 
1.382 
P=0.212 ᵇ 
  
Clinical Degradation “Global 
Health Status” 
  0.444 
p<0.001  ͣ
0.571 
p=0.081 ᵇ 
Clinical Degradation 
“Physical Functioning” 
  0.366 
p<0.001  ͣ
0.554 
p=0.089 ᵇ 
Clinical Degradation 
“Future Perspetive” 
  0.370 
p=0.002 ͣ 
0.595 
p=0.225 ᵇ 
Clinical Degradation 
“Arm Symptoms” 
  0.340 
p<0.001 ͣ 
0.537 
p=0.138 ᵇ 
RB - Relative Benefit; ARB - Adjusted Relative Benefit; RR - Relative Risk; ARR - Adjusted Relative Risk 
ͣ p-value obtained by the Chi-square test – Comparison, between the groups, of the percentage of individuals who obtained Clinical Improvement, 
Clinical Conservative Improvement, and Clinical Degradation, in the different global QoL scales, function, and symptoms, between the 1st and 3rd 
moments of evaluation after adjustment for the confounding variables at the baseline of the study. 
 In bold - Only the RB, aRB, RR, and aRR values that, still revealed a trend in  p-values (p <0.10) after adjustment for non-homogeneous factors 
at the baseline of the study.     
 
 
There were no statistically significant differences of the RR for the variable 
“Clinical Degradation” between the 1st and 6th month post-surgery, after 
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adjustment for non-homogenous factors at the baseline of the study. However, in 
the variable GHS (aRR = 0.571; p=0.081) and PF (aRR = 0.554, p = 0.089), the 
p-value showed a trend (p <0.10), which may suggest that the individuals in the 
Experimental Group had a lower risk of deterioration in these scales (Table 3). 
Most Important Results in the Analysis Performed Between the 1st and 9th 
Month after Surgery (n = 150) 
Analyzing the variable "Clinical Improvement", between the 1st and 9th 
month after surgery (1st and 4th moments of evaluation), after adjustment for 
non-homogeneous factors at the baseline of the study, the aRB value shows that 
the Experimental Group submitted to physiotherapy, had a higher proportion of 
patients with a substantial clinical improvement in the BRAS variable (aRB = 
1,761, p = 0.029), 76.1% higher than in the Control Group. In the other scales of 
function and symptoms there were no statistically significant differences. 
However, in the variable of the GHS “Clinical Improvement” (aRB = 1.639, p = 
0.054), the p-value reveals a trend (p <0.10) and the aRB value may suggest that 
the benefit, in this variable, was greater in the Experimental Group. In the 
analysis of the variable “Conservative Clinical Improvement”, between the 1st and 
9th  month after surgery, and with the use of the adjustment model, there were 
statistically significant differences in the GHS (aRB = 1.905, p = 0.038) and 
BRAS ( aRB = 1.761, p = 0.029). We can say that between the 1st and 9th 
month after surgery, the Experimental Group compared to the Control Group in 
the variable “Conservative Clinical Improvement” obtained a benefit of 90.5% on 
the GHS scale and 76.1% on the BRAS scale (Table 4). 
 
Table 4: Most important results (n = 150) in the analysis performed between the 1st and 9th month after surgery 
(1st and 4th moments of evaluation) 
Variable in Analysis RB aRB RR aRR 
Clinical Improvement 
“Global Health Status” 
2.074 
p<0.001  ͣ
1.639 
p=0.054 ᵇ 
- - 
Clinical Improvement 
“Physical Functioning” 
1.821 
p<0.001 ͣ 
1.274 
p=0.356 ᵇ 
- - 
Clinical Improvement 
“Future Perspective” 
1.545 
p=0.042  ͣ 
1.438 
p=0.231 ᵇ 
- - 
Clinical Improvement 
“Fatigue” 
2.54 
p<0.001 ͣ 
1.633 
p=0.104 ᵇ 
- - 
Clinical Improvement 
“Breast Symptoms” 
1.429 
p=0.001 ͣ 
1.322 
p=0.203 ᵇ 
- - 
 Clinical Improvement 
“Arm Symptoms” 
2.36 
p<0.001  ͣ
1.761 
p=0.029 ᵇ 
- - 
Conservative Clinical 
Improvement “Global 
Health Status” 
2.412 
p<0.001  ͣ
1.905 
p=0.038 ᵇ 
- - 
Conservative Clinical 
Improvement “Physical 
Functioning” 
2.278 
p<0.001 ͣ 
1.356 
p=0.341 ᵇ 
- - 
Conservative Clinical 
Improvement “Future 
Perspective” 
1.545 
p=0.042 ͣ 
1.438 
p=0.231 ᵇ 
- - 
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Conservative Clinical 
Improvement “Fatigue” 
2 
p<0.001 ͣ 
1.580 
p=0.124 ᵇ 
- - 
Conservative Clinical 
Improvement “Breast 
Symptoms” 
1.5 
p=0.014 ͣ 
1.5 
p=0.110 ᵇ 
- - 
Conservative Clinical 
Improvement “Arm 
Symptoms” 
2.36 
p<0.001  ͣ
1.761 
p=0.029 ᵇ 
 
- 
 
- 
Clinical Degradation 
“Global Health Status” 
- - 0.171 
p<0.001 ͣ  
0.287 
p=0.010 ᵇ 
Clinical Degradation 
“Physical Functioning” 
- - 0.361 
p<0.001 ͣ 
0.606 
p=0.150 ᵇ 
Clinical Degradation 
“Emotional Functioning” 
- - 0.558 
p=0.010 ͣ 
0.650 
p=0.188 ᵇ 
Clinical Degradation 
“Future Perspective” 
- - O.360 
p=0.001 ͣ 
0.562 
p=0.188 ᵇ 
Clinical Degradation 
“Pain” 
- - 0.535 
p=0.018 ͣ 
0.799 
p=0.529 ᵇ 
Clinical Degradation 
“Breast Symptoms” 
- - 0.388 
p=0.015 ͣ 
0.469 
p=0.186 ᵇ 
Clinical Degradation 
“Arm Symptoms” 
- - 0.230 
p<0.001  ͣ
0.361 
p=0.042 ᵇ 
RB - Relative Benefit; aRB - Adjusted Relative Benefit; RR - Relative Risk; aRR - Adjusted Relative Risk 
ͣ p-value obtained by the Chi-square test – Comparison, between groups, of the percentage of individuals who obtained a Clinical Improvement, 
Improvement with Conservative Clinical Relevance, and Clinical Degradation, in the different scales of function and symptoms, between the 1st and 
4th moments of evaluation. 
ᵇ p-value obtained by the Wald Test – Comparison, between groups, of  the percentage of individuals who obtained a Clinical Improvement, 
Improvement with Conservative Clinical Relevance and Clinical Degradation, in the different scales of function and symptoms, between the 1st and 
4th moments of evaluation with an adjustment for the confounding variables at the baseline of the study. 
In bold - Only the RB, aRB, RR and aRR values that still showed a statistically significant difference between groups after adjustment for non-
homogeneous factors at the baseline of the study. 
 
 
Table 4 shows that  there were statistically significant differences in the GHS 
(aRR = 0.287; p = 0.010) and BRAS (aRR = 0.361, p = 0.042) of the variable 
“Clinical Degradation” between the 1st and 9th month after surgery after 
adjustment for non-homogeneous factors at the baseline of the study. In these 
variables the physiotherapy may have acted as a protective factor between the 
1st and 9th month after surgery, as the Experimental Group registered a reduced 
risk of clinical GHS degradation (relative risk reduction of 71.3%) and of BRAS 
(relative risk reduction of 63.9%). 
In all of the analyses performed the estimate direction with an effect 
favorable to the Experimental Group was maintained, even in those variables 
that showed no statistically significant effect, after adjustment for confounding 
factors at the baseline of the study.  
Table 5 shows a Synthesis of the most important results of the study. 
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Table 5: Synthesis of the most important results of the study (statistically significant or in trend, after adjustment 
for confounding factors at baseline of the study) 
Variable in Analysis Evolution from the 
1st to the 2nd 
moments of 
evaluation (n=155) 
Evolution from the 
1st to the 3rd 
moments of 
evaluation (n=151) 
Evolution from the 
1st to the 4th 
moments of 
evaluation (n=150) 
Clinical Improvement “Global Health 
Status” 
aRB = 2.230 
p=0.014 
- aRB = 1.639 
p = 0.054 
Clinical Improvement “Arm 
Symptoms” 
- - aRB = 1.761 
p = 0.029 
Conservative Clinical Improvement 
“Global Health Status” 
- - aRB = 1.905 
p = 0.038 
Conservative Clinical Improvement 
“Arm Symptoms” 
- - aRB = 1.761 
p = 0.029 
Clinical Degradation 
“Global Health Status” 
aRR = 0.384 
p = 0.011 
aRR = 0.571 
p = 0.081 
aRR = 0.287 
p = 0.010 
Clinical Degradation 
“Physical Functioning” 
aRR = 0.484 
p = 0.035 
aRR = 0.554 
p = 0.089 
- 
Clinical Degradation 
“Future Perspective” 
aRR = 0.446 
p = 0.085 
- - 
Clinical Degradation 
“Arm Symptoms” 
aRR = 0.159 
p=0.007 
- aRR = 0.361 
p = 0.042 
P-value obtained by the Wald Test – Comparison, between groups, of the percentage of individuals who obtained a Clinical Improvement, 
Improvement with Conservative Clinical Relevance, and Clinical Degradation in the different global QoL scales, in function, and symptoms, 
between the 1st and 2nd moments of evaluation, between the 1st and 3rd moments of evaluation, and between the 1st and 4th moments of 
evaluation, after adjustment for the confounding variables at the baseline of the study 
 
 
Discussion 
 
The results of this Quasi - Experimental study show that a physiotherapy 
program can greatly improve QoL in women with breast cancer undergoing SLNB 
surgery during the first 9 months after surgery.  
In our literature review we found no other studies with a target population 
similar to ours. In many studies the protocol used in the experimental group did 
not match ours, regarding the frequency and type of intervention performed. We 
compared the results of our study with those performed regarding women 
undergoing breast cancer surgery with Axillary Lymph Node Dissection or SLNB 
and other oncological therapies, in which the experimental protocol included 
individual physiotherapy or specific treatment programs for women undergoing 
breast cancer surgery. 
The present study found that between the 1st and 3rd month after surgery  
the Experimental Group had a higher ratio of patients with a statistically 
significant improvement in the Global Health Status (aRB = 2,230). In the other 
variables, with no statistically significant effect after adjustment, the 
Experimental Group maintained the favorable estimate effect. This matches other 
studies that report a statistically significant GHS improvement in the same post-
surgery period in the group submitted to physiotherapy or to an exercise program 
when compared to a Control Group [19, 29, 31, 47]. In the other function and 
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symptoms scales there were no statistically significant differences between groups. 
This matches the results of other studies in which, during the same period, there 
were no statistically significant differences between groups in the scales for Arm 
Symptoms [48], Breast Symptoms [48, 49], Physical Functioning, Role 
Functioning, and Social Functioning [28, 48]. However, in some studies over the 
same period, there was a statistically significant improvement in the 
Experimental versus Control Group in Physical Functioning [19, 22, 31], Role 
Functioning [19, 22, 25], Emotional Functioning [19, 22], Social Functioning [19, 
22], Pain [19, 25, 29], Breast Symptoms [19], Arm Symptoms [19, 31], and 
Fatigue [25].  
 In our study, between the 1st and 3rd month after surgery, after adjustment 
for non-homogenous factors at the baseline of the study, the Experimental Group 
showed less degradation in the Global Health Status (relative risk reduction of 
61.6%), in Physical Functioning (relative risk reduction of 51.6%), and Arm 
Symptoms (relative risk reduction of 84.1%) when compared to the Control 
Group, suggesting that physiotherapy acted as a protective factor. We found only 
one reference to the effect of an exercise scheme in the degradation of the 
different dimensions of QoL during the first 3 months after surgery [47]. However, 
although the Experimental Group registered a lower degradation in the scales of 
Physical Functioning, Role Functioning, and Breast Symptomes, those authors 
[47] report no statistically significant differences between groups. 
In this study, between the 1st and 6th month after surgery, after adjustment 
for non-homogeneous factors at baseline of the study, we verified that there are 
no statistically significant differences between groups in “Clinical Improvement” 
and “Clinical Conservative Improvement”. However, the estimate direction with 
an effect favorable to the Experimental Group was maintained. These results are 
similar to those obtained in other studies in which 6 months after surgery women 
with breast cancer undergoing physiotherapy or a specific exercise program 
presented better scores, or a higher ratio with clinical improvement when 
compared to a Control Group (without the intervention of physiotherapy or an 
exercise program), but there were no statistically significant differences between 
groups in the Global Health Status [21, 23, 29], Physical Functioning [23, 50], 
Future Perspective [23], Fatigue [21, 23] or Arm Symptoms [23]. However, in 
other studies, 6 months after surgery women with breast cancer who had the 
support of physiotherapy or a specific exercise program, compared to a Control 
Group, showed statistically significant or clinically important improvement in 
Global Health Status [20, 22], Role Functioning [20, 22], Emotional Functioning, 
Social Functioning [22, 26], Fatigue [20], Pain [21], Future Perspective, Breast 
Symptoms, and Arm Symptoms [26]. 
 In the present study, between the 1st and 6th month after surgery, the p-
values of Global Health Status (aRR = 0.571) and Physical Functioning (aRR = 
0.554) demonstrated a trend level, suggesting that the Experimental Group had a 
lower ratio of patients with clinical deterioration in these variables. This matches 
other studies in which 6 months after the surgery, women with breast cancer who 
did not undergo physiotherapy, when compared to a group who did, registered a 
greater degradation in the Global Health Status [26, 27, 51], Physical 
Functioning, Role Functioning, Emotional and Social Functioning [50, 51], Body 
Image, Future Perspective [26], and Fatigue [51].  
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 Between the 1st and 9th month after surgery the Experimental Group had a 
higher ratio of patients with a clinical improvement in Arm Symptoms (aRB = 
1.761), as well as in the conservative clinical improvement of Global Health 
Status (aRB = 1.905) and Arm Symptoms (aRB = 1.761). These results are 
similar to those in other studies in which there was a statistically significant 
improvement at the 9th month after surgery in women with breast cancer who 
had the support of physiotherapy or an exercise program, when compared to 
women without the same type of support, in the scales of Global Health Status 
[24, 27, 52, 53, 54] and Arm Symptoms [54]. It should be noted that the studies 
by Travier et al. [51] and Gordon et al. [31] showed no statistically significant 
differences in the Global Health Status.  In our study we registered a greater 
clinical improvement in the Experimental VS. Control Group in the scales of 
Physical Functioning, Future Perspective, Fatigue and Breast Symptoms, but 
without statistically significant differences. This matches some studies in which, 
in the 9th month after surgery, women with breast cancer undergoing 
physiotherapy or a specific exercise program presented better scores, but there 
were no statistically significant differences between groups, in the scales of 
Physical Functioning [21, 31], Fatigue [21, 51], and Breast Symptoms [31].  
However, in other studies, in the same evaluation period, women with breast 
cancer who had the support of physiotherapy or an exercise program, when 
compared to women without that support, had statistically significant 
improvements in the scales of  Physical Functioning [23, 24, 27, 28, 52, 54], Social 
Functioning [21, 23, 28, 52], Role Functioning [27, 28, 52, 53], Emotional 
Functioning [28, 52, 53], Pain [21, 52, 53], and Breast Symptoms [27, 28, 30].  
 In the present study, 9 months after surgery the Experimental Group had a 
lower ratio of patients with a clinical degradation of Global Health Status (aRR 
= 0.287) and Arm Symptoms (aRR = 0.361). We did not find any studies that 
mentioned the effect of physiotherapy or exercise programs in the degradation of 
the global QoL scales, function, and symptoms after 9 months post-surgery. 
 The fact that there was no random selection / distribution of the patients 
over the study groups may have led to a lack of homogeneity of the groups at the 
baseline of the study in relation to some sociodemographic, clinical, and baseline 
scores variables. This can be a limitation, but we think it is important to mention 
that in the treatment of data, statistical techniques were used to correct for 
confounding factors at the baseline of the study. The multiple regression methods 
allowed us to control for confounding factors caused by the lack of basal 
homogeneity due to the selection bias [46]. 
 
 
Conclusion 
 
This study allowed us to reach the following conclusions with a statistically 
significant result or at a trend level of significance:  
• Physiotherapy contributes to the improvement of “Global Health Status” 
in women with Breast Cancer submitted to SLNB surgeries, between the 
1st and 3rd month post-surgery (clinical improvement 123% higher than 
that determined in the Control Group);  
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• Physiotherapy acts as a protective factor, reducing the risk of 
degradation in “Global Health Status” (61.6% reduction of degradation 
risk), “Physical Functioning” (51.6% reduction of degradation risk), and 
“Arm Symptoms” (84.1% reduction of degradation risk) between the 1st 
and 3rd month post-surgery for breast cancer with SLNB. In this period 
women who have access to physiotherapy present a better “Future 
Perspective”; 
• Physiotherapy acts as a protective factor against the degradation of 
“Global Health Status” and “Physical Functioning” in women submitted 
to breast cancer surgery  with SLNB  between the 1st and 6th month 
post-surgery (although without a statistical significance); 
• Physiotherapy contributes to the improvement of “Global Health Status” 
(clinical improvement 90.5% higher than in the Control Group) and 
“Arm Symptoms” (clinical improvement 76.1% higher than in the Control 
Group) between the 1st and the 9th month post-surgery in women with 
breast cancer undergoing SNLB surgery; 
• Physiotherapy acts as a protective factor between the 1st and 9th month 
post-surgery on breast cancer with SLNB, reducing the risk of 
degradation of “Global Health Status” and “Arm Symptoms” (63.9% 
reduction of degradation risk). 
 
We can conclude that physiotherapy contributes to the quality of care 
provided to women with breast cancer undergoing SLNB surgeries during the 
acute phase of survival. 
When we finalized this study, only women undergoing Axillary Lymph Node 
Dissection in breast cancer surgery could benefit from physiotherapy sessions in 
the IPOLFG. The evidence produced by this research made it possible to propose 
an alteration to this protocol, suggesting that all women with breast cancer 
should be submitted to an early physiotherapy program and a functional follow-
up model throughout all stages of survival. 
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